Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05806931 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

Study acronym: SCOTI
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 18, 2026 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Enrollment target: 55 to 50v4
  3. Start date changed from estimate of May 1, 2023 to May 17, 2023v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 7 to 9
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)
Trial Details
NCT Number NCT05806931
Lead Sponsor Rutgers, The State University of New Jersey
Conditions
(from sponsor)		 Colon Cancer, Rectal Cancer
Related terms Colonic Neoplasms, Rectal Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov